Since genetic deletion or pharmacological inhibition of RANK delays the onset and even prevents Brca1 and Brca1;p53 mutation-driven mammary tumors, we speculated that RANKL/RANK might affect proliferation and expansion of mammary progenitor cells. This evidence concerns the gene TP53 and breast cancer.